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Abstract 
Lymph drainage rate in both arms is greater in women destined to develop breast cancer-related 
lymphoedema (BCRL) than in those who do not develop BCRL, indicating a constitutive 
predisposition. We explored constitutive differences here, measuring the maximum pressure (Ppump) 
and rate of 99mTc-Nanocoll transport generated by the contractile arm lymphatics before breast 
cancer surgery in 26 women who were followed for 2 years to determine their eventual BCRL/non-
BCRL status. Ppump and tracer transport rate in the ipsilateral arm were measured by lymphatic 
congestion lymphoscintigraphy pre- and post-surgery. BCRL occurred in 10/26 (38.5 %) cases. Ppump in 
the women who later developed BCRL (40.0 ± 8.2 mmHg) was 1.7-fold higher than in those who did 
not develop BCRL (23.1 ± 10.8 mmHg, P = 0.001). Moreover the rate of lymph tracer transport into 
the forearm was 2.2-fold greater in the arms of women who later developed BCRL (P = 0.052). 
Surgery did not significantly reduce Ppump at 21 weeks but impaired forearm tracer transport in pre-
BCRLs by 58 % (P = 0.047), though not in non-BCRLs. Women destined to develop lymphoedema 
have higher pumping pressures and lymph transport, indicating harder working lymphatics prior to 
cancer treatment. Axillary lymphatic damage from surgery appears to compromise lymph drainage 
in only those women constitutively predisposed but not in those women with constitutively lower 
lymphatic pressures and transport. 
 
Clinical Perspectives 
 Breast cancer-related lymphoedema (BCRL) is a common sequel to breast cancer treatment but 
recent findings indicate that axillary surgery is not the sole cause. 
 A constitutive predisposition to BCRL emerges from the prospective study reported here in 
which BCRL-destined patients were found to generate higher lymphatic pumping pressures and 
had faster lymph transport than non-BCRL patients before surgery.  
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 The higher apparent lymphatic work rate in the pre-BCRL patients may make this population 
more susceptible to (even minor) axillary trauma, tipping them into chronic lymphatic failure. 
The pathophysiology of BCRL is analogous to high preload and high afterload cardiac failure in 
systemic hypertension. Pharmacological interventions aimed at reducing lymphatic pre- and/or 
afterload should, in theory, prevent BCRL if introduced earlier enough in at risk patients. 
 This suggests, in theory, that women with higher lymphatic preloads could be identified as an ‘at 
risk’ group prior to cancer treatment. 
 
Summary statement 
The risk of developing lymphoedema after breast cancer treatment is not attributable solely to 
axillary lymphatic obstruction, but also depends on a constitutive predisposition through higher 
lymphatic preload, which makes some women more vulnerable to the axillary interventions. 
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Introduction 
Breast cancer-related lymphoedema (BCRL) is a common sequel to breast cancer treatment, the risk 
of which is increased by obesity, extensive axillary lymph node dissection and radiotherapy to the 
regional lymph nodes (DiSipio et al. 2013; Basta et al. 2015; Whelan et al. 2015). The 
pathophysiological basis of BCRL is complex and the former assumption of regional lymphatic 
obstruction to the ipsilateral arm following axillary trauma (stopcock hypothesis) is an incomplete 
explanation. Features of BCRL not readily explained by a simple stopcock hypothesis include sparing 
of many breast cancer patients despite extensive axillary surgery; the occurrence of BCRL in patients 
after only sentinel lymph node biopsy; delayed onset of swelling; and non-uniformity of the swelling 
along the arm. Moreover the contralateral arm does not appear to be normal in women with 
unilateral BCRL; it exhibits lymphatic capillary dilatation in the dermis and greater contralateral hand 
lymph drainage when there is ipsilateral hand swelling (Mellor et al. 2000; Stanton et al. 2006b). 
A striking recent finding was that women who later develop BCRL have higher lymph 
drainage rates in both arms, in both the muscle (+22–29 %) and subcutis (+22–50 %), before any 
swelling is evident, compared with women who do not later develop BCRL (Stanton et al. 2009a). 
The raised lymph drainage rates were observed at 7 months post-surgery, so they could have been 
either a systemic effect of the cancer treatment or an inherent, constitutive property. To resolve this 
point a recent prospective study examined breast cancer patients before the cancer surgery. 
Quantitative lymphoscintigraphy was performed before surgery and the patients followed for 13 
months post-surgery. In the 7 out of 38 patients (18 %) who developed BCRL, the pre-operative 
lymph removal rate constant k was 16 % higher than in patients who did not later develop BCRL 
(Bains et al. 2015). These findings, along with those of Stanton et al. (2006b, 2009a) and Mellor et al. 
(2000), indicate that there are constitutive, pre-operative, bilateral differences in lymphatic 
physiology in BCRL-destined patients. Lymphatic drainage involves active contractile pumping, both 
in animal models (McHale & Meharg 1992; Li et al. 1998; McCloskey et al. 2002; von der Weid et al. 
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2014) and human limbs (Olszewski & Engeset 1980). To assess lymphatic collector vessel pump 
function in the arms of women with established BCRL, pump function was quantified as the 
maximum pressure (Ppump) generated in the collector lymphatics when lymph flow was blocked by 
inflating a cuff around the upper arm (lymphatic congestion lymphoscintigraphy, Modi et al. 2007). 
Ppump was found to be significantly impaired in the lymphoedematous arm, by 38 % relative to 
healthy control subjects. Moreover there was a strong negative correlation between Ppump and the 
magnitude of the swelling, i.e. the weaker the pump, the greater the swelling. 
To bring together many of the findings reviewed above, we proposed the following working 
hypothesis (Stanton et al. 2009b). In pre-BCRL patients the work of lymphatics is already high due to 
their raised fluid load. After axillary surgery, lymphatic pump failure may then develop in a manner 
analogous to cardiac failure following a chronically raised afterload (hypertension). Lymphatic 
afterload is probably increased chronically by axillary node damage during surgery and radiotherapy, 
since nodal excision raises lymph outflow resistance in sheep (Kim et al. 2003). The chronically 
increased work by the lymphatic muscle fibres leads eventually to reduced lymphangion 
contractility, as in hypertensive heart failure; animal studies show lymphatic failure at increased 
distending pressures (Li et al. 1998; Levick & McHale 2003; Davis et al. 2012). The resulting decline in 
lymph drainage rate leads to oedema in the drainage territory of the failing lymphatics. The chronic 
pump failure hypothesis offers a rational explanation for the variable delay in onset of BCRL, since a 
variable period is likely to be required for overload failure to reach a critical point. Pump failure can 
also offer a rational explanation for the regionality paradox (Modi et al. 2005; Stanton et al. 2009b); 
if the constitutionally weakest lymphatic collector vessels fail first, swelling will be localised to their 
drainage territory, i.e. hand, forearm or upper arm. 
In light of the constitutive, pre-operative differences in lymph flow in lymphoedema-
destined breast cancer patients, the question arose as to whether these patients might also have 
constitutive differences in lymphatic pump function prior to pump failure. The present study 
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evaluates this possibility by measuring maximal lymphatic pump pressure Ppump, plus several 
secondary measures of lymphatic transport rate, in the ipsilateral arm of women recently diagnosed 
with breast cancer. The study was carried out on the ipsilateral arm before and after axillary surgery, 
and the patients were then followed for 2 years to see who did and who did not develop BCRL. 
 
Patients and Methods 
Patients 
The study was approved by the National Research Ethics Service (reference 09/H0701/112) and the 
Administration of Radioactive Substances Advisory Committee (ARSAC) (certificate number 
295/3230/25986). Procedures were carried out in accordance with the Declaration of Helsinki (2013) 
of the World Medical Association. All patients gave written informed consent. Twenty-six women, 
aged 53 ± 12 (S.D.) years and recently diagnosed with breast cancer, were recruited from the Breast 
Clinics at St George’s Hospital, London; The Royal Marsden Hospital, Sutton, Surrey; and Croydon 
University Hospital, Croydon, Surrey. Details of the breast cancer and its treatment are summarised 
in Table 1. Patients underwent mastectomy or wide local excision, and axillary lymph node clearance 
surgery (ANC) or sentinel lymph node biopsy (SLNB), as recommended by the multidisciplinary team. 
All patients received radiotherapy. 
Baseline arm assessment and lymphatic congestion lymphoscintigraphy (LCL) were 
performed before axillary surgery (the pre-surgical visit) and repeated 21 ± 15 (S.D.) weeks after 
surgery (the post-surgical visit). Diagnostic arm assessment for lymphoedema (without LCL) was 
performed at 13.0 ± 2.8 months and 25.0 ± 4.7 months post-surgery, and also shortly after BCRL 
onset in the BCRL patients. In 6 patients the post-surgical LCL was not performed because the 
patients were unavailable or declined, but these patients were nevertheless followed to see whether 
or not they developed BCRL. Height was measured pre-surgery and weight was recorded on all visits 
to calculate body mass index (BMI). The breast cancer patients who later developed BCRL will be 
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referred to as ‘pre-BCRL’ patients, and the patients who did not develop BCRL as ‘non-BCRL’ 
patients. The ipsilateral arm of the pre-BCRL patients was the dominant side in 40 % of cases and the 
non-dominant arm in 60 %; in the non-BCRL patients the ipsilateral arm was the dominant side in 44 
% of cases and the non-dominant side in 56 %. 
 
Assessment of the arm for lymphoedema 
Arms were assessed both by clinical criteria and by volume measurement. The clinical features of 
lymphoedema are evident at an early, minor stage that is not readily demonstrated by whole-arm 
volume measurement, because arm volumes can change with change in body mass after cancer 
treatment (see Results). For this reason the diagnosis of BCRL was made clinically, rather than on 
arm volumes per se. The diagnosis of BCRL was always confirmed independently by a Lymphoedema 
Practitioner. Clinical assessment was performed as described by Stanton et al. (2006a). Briefly, 
lymphoedema was considered to be present if any of the following were detectable: (i) decreased 
visibility of subcutaneous veins on the ventral forearm and dorsal hand; (ii) smoothing or fullness of 
the medial elbow and distal upper-arm contours; (iii) increased skin and subcutis thickness if the 
tissues are pinched between finger and thumb; (iv) pitting oedema upon application of thumb 
pressure for 60 s. In addition, the thickness of the posterior axillary fold (PAF) was assessed by the 
‘pinch test’ (Roberts et al. 1995). Patients with ipsilateral PAF thickening also had arm oedema. In 
addition to the clinical assessment, the volume of each arm was measured between the ulnar styloid 
process (wrist) and anterior axillary fold (upper arm) using an opto-electronic limb volumeter 
(Perometer 350S, Pero-System Messgeräte GmbH, Wuppertal, Germany), as evaluated by Stanton et 
al. (1997). 
 
Lymphatic congestion lymphoscintigraphy (LCL) 
LCL was performed as described by Modi et al. (2007) with minor changes (below). To check the 
efficacy of tissue compression by the upper arm congestion cuff, preliminary experiments were 
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performed in which antecubital venous pressure (Pv) was compared directly with the applied cuff 
pressure (Pcuff) in the arms of 6 healthy participants. The participant reclined on a bed with the 
forearm heart level. A cannula (Venflon 18G) was inserted into the antecubital vein and connected 
via fine bore tubing containing heparinised saline to a calibrated pressure transducer (SensoNor 
dome transducer and BPM-832 pressure amplifier; Linton Instrumentation, Diss, Norfolk). Pv was 
displayed on a computer based data recording system (PowerLab 4/30 and LabChart, AD 
Instruments; PMS Ltd, Maidenhead, Berkshire). A standard blood pressure cuff around the upper 
arm was inflated in a series of steps over the range 22–46 mmHg. Pv increased in parallel with the 
increases in Pcuff, albeit with absolute values 2.9–3.1 mmHg less than Pcuff. These results showed that 
the congesting cuff pressures were transmitted to the deeper tissues with minor attenuation, in 
accordance with the routine use of congesting cuffs to measure arterial blood pressure. 
For the LCL study the patient lay supine on a bed and the brachial artery blood pressure (BP) 
was measured by auscultation from the contralateral arm using a mercury sphygmomanometer and 
a Riva-Rocci congestion cuff (AC Cossor & Son Ltd, London). For 2 patients with particularly large 
arms the larger, alternative cuff size was used, and the standard size for all others. The cuff was 
secured around the ipsilateral upper arm with the tubing at the top and the cuff bladder centred 
anteriorly. The cuff was wrapped closely and evenly around the arm and the overlap fastened down 
with adhesive tape. The sphygmomanometer was then reattached to the cuff. The arm was 
supported so that the forearm was horizontal and at heart level. The gamma camera (Argus Epic; 
MIC Ltd, Fleet, Hampshire) (128 x 128 matrix, low-energy general purpose collimator) was 
positioned above the ipsilateral arm for ventral viewing, with the forearm, upper arm, axilla, and 
adjacent part of the trunk within the field of view. Patients acclimatised to their surroundings for 45 
min, including 20 min whilst lying down before the tracer injection and scan. The ambient laboratory 
temperature was 24.0 ± 0.6 (S.D.) C (n = 26) on the pre-surgical visit and 23.8 ± 0.6 C (n = 20) post-
surgery. Skin temperature, recorded from the ipsilateral forearm (YSI 4600 digital thermometer; 
Henleys Medical Supplies Ltd, Welwyn Garden City, Hertfordshire), was 29.6 ± 1.3 °C pre-surgery and 
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29.5 ± 1.5 °C post-surgery. The cuff was inflated to 60 mmHg (or 50 mmHg if the diastolic BP was < 
60 mmHg), using the sphygmomanometer. After 2 min of congestion, 50 l of 99mTc-Nanocoll (GE 
Healthcare, Hatfield, Hertfordshire) of activity 8.4 ± 1.6 MBq (n = 26) was injected intradermally 
between the 2nd and 3rd metacarpal heads of the ipsilateral hand, using a microneedle of outer 
diameter 0.2 mm (Unimed SA, Lausanne, Switzerland). The equivalent radiation dose was 0.03 mSv. 
The injections were performed consistently and by the same operator throughout, taking on average 
52  13 s (n = 26) to complete. The injected activity was 8.1  1.5 MBq and the duration of the 
injection was 57  16 s for the pre-BCRL group, and 8.6  1.6 MBq and 49  11 s for the non-BCRL 
group (n = 10 and 16, P = 0.41 and 0.18, unpaired t tests). Lymphatic density is higher in the dermis 
than subcutis, so dermal injections provided rapid access of the tracer to the hand and arm collector 
lymphatics for gamma-camera imaging (Stanton et al. 1999b; O’Mahony et al. 2004; Mellor et al. 
2010). Lymphatic vessels are not readily imaged following intramuscular administration of 
radiotracer in the arm (Stanton et al. 2003). 99mTc-Nanocoll was used as the lymphatic tracer instead 
of Technescan HIG (human IgG), used formerly (Modi et al. 2007), because Technescan HIG had 
been withdrawn by the sole manufacturer. Radiochemical purity of the 99mTc-Nanocoll was 95–100 
%. 
As soon as the injection was complete, a dynamic sequence of 40 x 2.5-min acquisitions was 
commenced, total duration 70 min. The cuff pressure (Pcuff) was held at 60 mmHg for 10 min, a 
period long enough to demonstrate trapped tracer unable to pass beyond the lower border of the 
cuff. Pcuff was then deflated in 10 mmHg steps every 10 min until Pcuff = 0 mmHg. A further static 
image was acquired after completion of the dynamic sequence but while the patient remained in 
position, namely an outline of the forearm, upper arm, cuff and shoulder region drawn on the 
camera face using a 57Co pen marker (High Technology Sources Ltd, Didcot, Oxfordshire) to create a 
template for the region of interest analysis (see below). The syringe activity was measured before 
and after injection using the gamma camera, to calculate the injected activity. No blood samples 
were collected. 
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Measurement of lymphatic function 
Three regions of interest (ROI) were analysed, namely the forearm (ROI1), the subcuff region of the 
upper arm (ROI2), and the axillary-supraclavicular region (ROI3) (Figure 1). The counts from each 2.5 
min acquisition were plotted against time for each ROI. At high cuff pressures the tracer was 
transported into the forearm and on towards the lower border of the cuff, but was unable to move 
more proximally because the lymphatic pump was unable to generate sufficient pressure to 
overcome the cuff pressure. As cuff pressure was reduced, there came a point at which lymphatic 
pressure was high enough to force tracer under the cuff and into the axilla. 
Primary measure of lymphatic function, Ppump (mmHg)   Ppump was defined as the Pcuff at which 
radioactivity in ROI3 (axilla) first exceeds the background level (Modi et al. 2007). 
Secondary indices of lymphatic transport   The secondary indices of lymphatic transport, derived 
using fractional counts (local counts divided by injected activity), were (1) the rate of rise of 99mTc-
Nanocoll activity in ROI1 during the initial 2.5–10.0 min period of trapped lymph (dA/dtROI1, min-1); 
(2) the maximum 99mTc-Nanocoll count in ROI1; and (3) the rate of rise of 99mTc-Nanocoll activity in 
ROI3 over the virtually linear, 20 min segment of the counts-versus-time plot after Ppump exceeded 
Pcuff. Linear transport occurred at 35–55 min for the pre-BCRL group and 42.5–62.5 min for the non-
BCRL group (dA/dtROI3, min-1). All counts were decay corrected with standardisation to the injection 
time. 
 
Statistical analysis 
Results are presented as the mean ± standard deviation (S.D.) in the text and as the mean ± standard 
error of the mean (S.E.M.) in the tables and figures. The normality of data sets was tested using the 
D’Agostino-Pearson Omnibus test. Student’s paired or unpaired t test was used to compare 
differences between groups, or the Mann-Whitney test in the case of non-Gaussian distribution 
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(comparison of Ppump in the pre-BCRL and non-BCRL groups). The foregoing together with linear 
regression and two-way analysis of variance (ANOVA) were as implemented in GraphPad Prism 
version 6 (GraphPad Software, La Jolla, CA, U.S.A.). Differences were considered significant if P ≤ 
0.05. 
 
Results 
Clinical, surgical and morphometric data 
Incidence of BCRL and cancer treatment   BCRL was diagnosed clinically in 10/26 women (38.5 %), 
with onset at 7 ± 4 months (0–12 months) post-surgery. BCRL developed in 7/14 (50.0 %) patients 
receiving a mastectomy, 3/12 (25.0 %) patients receiving wide local excision, 9/19 (47.4 %) patients 
receiving axillary node clearance, and 1/7 (14.3 %) receiving sentinel node biopsy. The number of 
lymph nodes removed in the pre-BCRL group, 15.8 ± 9.5 per patient, was not significantly different 
from non-BCRL, 13.2 ± 10.5 (P = 0.53, unpaired t test). The number of removed nodes that were 
positive for cancer was again similar in the two groups (4.3 ± 3.6 pre-BCRL versus 3.3 ± 4.2 non-BCRL, 
P = 0.54). 
Arm volumes   Before surgery both the ipsilateral and contralateral arm volumes for the pre-BCRL 
group were larger than for the non-BCRL group, by 22.1 % (P = 0.055, unpaired t test; Table 2) and 
21.5 % respectively (P = 0.054). Surgery had no statistically significant early (i.e. at mean 21 weeks) 
effect on arm volume in either the pre-BCRL or non-BCRL group (Table 2; P = 0.31 and 0.48 for pre-
BCRL ipsilateral and contralateral arms respectively; P = 0.80 and 0.64 for non-BCRL, paired t tests). 
However the above analysis hides a significant difference (Table 2); after surgery, ipsilateral volumes 
were significantly greater than contralateral volumes in the pre-BCRL patients (P = 0.04), due to 
small, divergent changes; there was a small increase in ipsilateral volume (not itself statistically 
significant) and a small fall in contralateral volume (not itself statistically significant), resulting in a 
significant difference between the arms (Figure 2). Over 2 years ipsilateral arm volume tended to 
increase with time in the pre-BCRL group, as expected, but not in the non-BCRL group or 
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contralateral arms. In some cases the increase in ipsilateral arm volume was very small, especially at 
the time of diagnosis, emphasising the importance of using clinical criteria to diagnose early 
lymphoedema (Stanton et al. 2006). 
Body mass index (BMI)   Prior to surgery the pre-BCRL group’s mean BMI (29.5 ± 5.0 kg/m2) was 20 
% higher than that of the non-BCRLs (24.7 ± 3.6 kg/m2), in keeping with their 22 % greater arm 
volumes. Higher BMI is a known risk factor for BCRL (McLaughlin et al. 2008; DiSipio et al. 2013); our 
arm volume data indicate that this related parameter is a risk factor. BMI did not change significantly 
up to 25 months post-surgery (P = 0.044 for pre-BCRL BMI versus non-BCRL BMI, P = 0.98 for time-
points; two-way ANOVA). 
 
Tracer movement along the lymphatic system of the arm 
Representative images from a dynamic scan of a pre-BCRL, pre-surgical patient are shown in Figure 
1. The radiotracer entered the hand and forearm lymphatics rapidly, in some cases while the 
injection was still in progress (< 1 min). After the injection was complete, the tracer traversed the 
distance from the hand depot to the distal border of the cuff (mean distance 30.4 cm) at a velocity of 
7.2 ± 4.3 cm/min (n = 26). Up to 3 (mean 1.6) lymph tracks were imaged in the forearm during pre-
surgical LCL and 1–4 (mean 1.7) tracks during the post-surgical LCL. Dermal rerouting of lymph 
drainage was not evident in any patient, either pre- or post-surgery. Tracer accumulated at the distal 
border of the congestion cuff until the pressure in the cuff was lowered sufficiently to allow tracer to 
pass under the cuff (ROI2) and into the axilla (ROI3). 
 
Comparison of lymphatic function in the pre-BCRL and non-BCRL patients before surgery 
Ppump before surgery   Maximal lymphatic pump pressure in the pre-BCRL and non-BCRL groups was 
compared at the pre-surgical time-point, in order to test the hypothesis that there is an early, 
constitutive difference in lymphatic pumping in pre-BCRL women. Individual Ppump values are plotted 
in Figure 3. Ppump in the pre-BCRL group (40.0 ± 8.2 mmHg) was on average 73 % higher than Ppump in 
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the non-BCRL group (23.1 ± 10.8 mmHg, n = 10 and 16). The marked difference in pump pressure 
was highly significant (P = 0.0007, Mann-Whitney test). A bimodal distribution of Ppump has been 
reported in healthy individuals previously (Modi et al. 2007). It is interesting to note that when the 
Ppump values of both pre- and non-BCRL groups are pooled, a bimodal distribution is evident (Figure 
3, right array). This raises the possibility that two human populations, with high and low Ppump 
respectively, account for the bimodality in the data of Modi et al. (2007). 
Lymphatic transport dynamics before surgery   There were large differences in the lymphatic 
transport of 99mTc-Nanocoll between the two groups before surgery. These are illustrated in Figure 
4A, B, which shows the time-course of activity in each of the three ROIs over the duration of the 70 
min scan. Several features distinguished the pre-BCRL from the non-BCRL group. (i) The rate of rise 
of tracer activity in ROI1 during the initial trapped lymph phase (2.5–10.0 min), dA/dtROI1, was faster 
in the pre-BCRL patients that in the non-BCRL patients. (ii) The peak, accumulated activity in ROI1 
during the trapped lymph phase was higher in pre-BCRL than non-BCRL patients. (iii) The rate of rise 
activity in ROI3 after tracer began to be pumped beyond the cuff, dA/dtROI3, was faster in pre-BCRL 
than non-BCRL patients. Data analysis (Table 3) showed that dA/dtROI1 for pre-BCRL patients was 
approximately double that for non-BCRL patients (P = 0.052) and dA/dtROI3 for pre-BCRL patients was 
1.55 times higher than for non-BCRL (P < 0.0001). All four measures of lymphatic function were thus 
consistent with a more active lymphatic pump in pre-BCRL patients compared with non-BCRL 
patients. 
 
Comparison of lymphatic function before and soon after surgery 
Pre-BCRL patients, before versus soon after surgery   The marginal decline in Ppump from 40.0 ± 8.2 
mmHg prior to surgery to 36.7 ± 10.0 mmHg at 21 weeks after surgery was not statistically 
significant (n = 9 pairs, P = 0.50, paired t test). By contrast, the indices of lymphatic transport in pre-
BCRL patients were all significantly lower at 21 weeks post-surgery (Figure 5).  During the trapped-
lymph phase, dA/dtROI1 post-surgery fell to 42 % of its pre-surgery level (P = 0.047, comparison of 
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slopes) and the maximum count in ROI1 fell to 51 % of the pre-surgery level (P = 0.025, n = 9, paired 
t test). When cuff pressure was lower than lymph pressure, dA/dtROI3 post-surgery fell to 27 % of the 
pre-surgery level (P < 0.0001, comparison of slopes). 
Non-BCRL patients, before versus soon after surgery   Surgery had much less effect on the 
lymphatic system in non-BCRL patients than in pre-BCRL patients. Ppump was well maintained at 21 
weeks after surgery in the non-BCRL patients (pre-surgery 23.1 ± 10.8 mmHg, post-surgery 24.5 ± 
11.3 mmHg; n = 11 pairs, P = 0.78, paired t test). The two lymphatic transport indices for ROI1 were 
likewise little changed post-surgery (Figure 5); dA/dtROI1 was not reduced (21 % increase not 
significant, P = 0.56) and the maximum count in ROI1 was not reduced (20 % increase not significant, 
P = 0.32, n = 11). dA/dtROI3 declined a little post-surgery, by 28 % (P = 0.0008), but this was a 
relatively small change compared with the 73 % fall in dA/dtROI3 in the pre-BCRL patients (Figure 5). 
Comparison of pre-BCRL versus non-BCRL patients soon after surgery   After surgery Ppump for the 
pre-BCRL group (36.7 ± 10.0 mmHg, n = 9) still exceeded that of the non-BCRLs (24.5 ± 11.3 mmHg, n 
= 11) but the difference was smaller than before surgery (12.1 mmHg; P = 0.022, unpaired t test). 
Because dA/dtROI1 in the pre-BCRL group had been greatly reduced by surgery, it was no longer 
higher than in the non-BCRL group (P = 0.45).  The same was true for peak activity in ROI (P = 0.18). 
In the case of dA/dtROI3, the decrease caused by surgery in the pre-BCRL group was so large that the 
pre-BCRL value after surgery was significantly lower than in the non-BCRL group (P = 0.0003). 
 
Discussion 
The primary aim of this study was to test the hypothesis that women destined to develop arm 
lymphoedema after breast cancer treatment have constitutive differences in arm lymphatic 
physiology. The previous evidence underlying the hypothesis was summarised in the Introduction 
and included raised lymph flows in pre-BCRL women (Stanton et al. 2009a, Bains et al. 2015). The 
present data, obtained before axillary surgery or radiotherapy, support the hypothesis; the results 
showed highly significant differences in lymphatic pump pressure and lymph tracer transport 
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between those who later developed BCRL and those who did not. Moreover the data indicate a 
more active, not weaker lymphatic system in the pre-BCRL women. By contrast, once long-standing 
lymphoedema is present (mean 7.4 years), Ppump is reduced, indicating a weakened lymphatic pump 
(Modi et al. 2007). The second main finding was that although the breast cancer treatment did not 
cause a significant, early (21 week) fall in lymphatic pump pressure, it did cause striking reductions in 
forearm lymph transport rates in the pre-BCRL patients, with relatively little effect in non-BCRL 
patients. Thus, whereas a marked fall in pump pressure is a later event in lymphoedema 
development (Modi et al. 2007), our new results reveal evidence of impaired lymphatic transport 
rates within 5 months of treatment. 
 
Arm volumes, incidence of BCRL and risk factors 
We applied strict clinical criteria, developed previously, for the diagnosis of BCRL (Stanton et al. 
2006). The diagnosis of early, mild BCRL based purely on arm volume measurement can be 
confounded by other factors, such as weight change, that affect arm size (Miller et al. 2013; Vagenas 
et al. 2015). The incidence of BCRL (38.5 %) is within the range reported in recent studies; meta-
analysis of nine prospective cohort studies gives an incidence of BCRL diagnosed by more than one 
method of 28.2 % (mean; range 11.8–53.5 %) (DiSipio et al. 2013). Nevertheless the question arises 
as to whether 2 years is sufficient follow-up; DiSipio et al. reported that the incidence of BCRL 
increases up to 2 years after diagnosis or surgery (24 studies), whereas two questionnaire studies 
reported an increase beyond 2 years (Paskett et al. 2007; Norman et al. 2009). Paskett et al. (2007) 
reported that whereas the estimated prevalence (repeated episodes or continuous swelling) was 
23–29 % for any assessment interval, the incidence of episodic swelling increased beyond 2 years (48 
% at 2 years, 54 % at 3 years). Norman et al. (2009) reported an increase in cumulative incidence 
from 30 % at 2 years to 41 % at 5 years. Data from objective and subjective measures of 
lymphoedema rates can show considerable discordance (McLaughlin et al. 2008). In the present 
study all cases of BCRL developed within 12 months of surgery and were diagnosed according to 
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strict clinical criteria with confirmation by a Lymphoedema Practitioner; no cases arose in the second 
year. 
The study was not designed to identify risk factors for BCRL but nevertheless showed that 
BCRL incidence was 3.3-fold higher in the patients receiving axillary clearance than SLNB. Axillary 
clearance surgery is a known risk factor for BCRL (McLaughlin et al. 2008). The number of lymph 
nodes removed and the number positive for cancer were very similar for each group. Higher BMI is 
an established risk factor for BCRL (McLaughlin et al. 2008; DiSipio et al. 2013), and was significantly 
higher in the pre-BCRL than the non-BCRL group, by 20 %; consistent with this was the 22 % greater 
ipsilateral and contralateral arm volumes in the pre-BCRL group, indicating that arm volume is a 
related risk factor. It is currently unknown whether pre-surgical arm volume is an independent risk 
factor for BCRL. 
 
Constitutively raised lymphatic function in the BCRL-destined group 
The results in Figure 3 showed that collector lymphatics distal to the cuff in pre-BCRL patients were 
able to pump lymph to a higher maximal pressure than those in non-BCRL patients. Moreover the 
faster dA/dtROI1 and higher maximum activity in ROI1 of pre-BCRL patients indicated a more rapid 
transport of lymph from the hand depot into the collector lymphatics of the forearm; and the faster 
dA/dtROI3 indicated a more rapid transport of lymph into the axilla after Ppump exceeded Pcuff. These 
findings combine to support the hypothesis of constitutively enhanced lymphatic function in 
lymphoedema-destined women. 
 
LaPlace’s law and the raised Ppump 
What mechanism(s) might underlie the pre-operative difference in Ppump between the two groups? 
LaPlace’s law states that the pressure P generated by tension T in a thin-walled tube of radius R 
equals T/R. This raises the question of whether the lymphatic smooth muscle contractile force T is 
17 
 
greater in pre-BCRL than non-BCRL patients, or whether the collector vessel radius R is smaller. 
Although we have no direct evidence on this point, increased lymphatic smooth muscle activity 
(force and/or frequency of contraction) seems the more likely explanation, because the raised 
dA/dtROI1 and maximum ROI1 activity indicate an increased rate of lymph transport (flow) - a finding 
broadly in keeping with the raised lymphatic drainage rate constant k in pre-BCRL patients reported 
by Bains et al. (2015). Limited evidence against a smaller vessel radius comes from the observation 
of wider initial lymphatics in the contralateral arm of women with BCRL when compared with the 
arms of non-BCRL breast cancer patients (Mellor et al. 2000); dilated lymphatic collectors imaged in 
BCRL arms (median duration 24 months) by magnetic resonance lymphangiography (Liu & Wang 
2014), and (in early lymphoedema) collector vessel ectasia observed in histological sections from 
secondary lymphoedema of the leg (Mihara et al. 2012). Studies employing X-ray lymphangiography 
have demonstrated dilated lymphatic collectors in BCRL and also following axillary dissection but in 
the absence of arm swelling (Abe 1976; Clodius 1977; Mortimer 2003). 
 
Possible causes of raised Ppump 
Assuming that the high Ppump, along with the other indices, indicates enhanced lymphatic contractile 
force in pre-BCRL patients, what might cause this? A possible factor is the physiological adaptation of 
lymphatic smooth muscle, either by hypertrophy or raised contractility, to the chronically high fluid 
load (preload) in pre-BCRL patients. A high fluid load is indicated by the raised lymphatic removal 
rate constant k in pre-BCRL patients (Stanton et al. 2009a; Bains et al. 2015). This is supported by the 
recent report of raised capillary filtration capacity in both forearms of BCRL patients relative to the 
arms of matched breast cancer patients without BCRL (Jensen et al. 2015), although equivalent data 
from pre-BCRL patients is lacking. Also, the findings were based on short (3–4 min) congestions and 
are contrary to results based on the classic, longer congestion method (Stanton et al. 1999a) 
Physiological adaptation of lymphatic smooth muscle to a constitutively high resistance axillary node 
pathway (afterload) is an additional, speculative possibility. In single lymphangions from the rat 
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mesentery, in which input and output pressures were controlled, elevated afterload triggered a 
time-dependent increase in lymphatic contractility, modulated by change in preload (Davis et al. 
2012; Scallan et al. 2012). Genetic factors have also been related to BCRL susceptibility (Finegold et 
al. 2008; Newman et al. 2012; Leung et al. 2014). 
 
Hypothesis linking raised Ppump in pre-BCRL and subnormal Ppump in established BCRL; 
potential key role of lymphatic collector vessel smooth muscle work 
Not only is Ppump in established BCRL lower than the Ppump of normal, healthy subjects but also the 
severity of the swelling correlates negatively with Ppump indicating that partial failure (weakening) of 
the collector lymphatic pump over the years contributes to the pathogenesis of BCRL (Modi et al. 
2007). The new findings here raise the question ‘why would women with intrinsically stronger 
lymphatic pumps than others be more prone to pump failure after surgery?’. The high transport 
rates in the pre-BCRL patients (Figure 4A), along with their high lymph flows (Stanton et al. 2009a; 
Bains et al. 2015) offers a rational, albeit speculative explanation, as follows. The stroke work of a 
contracting lymphangion equals the volume of lymph ejected (V) x active pressure increase (P). 
Lymphangion work rate = (V/t) x P, i.e. lymph flow x P. The high lymph flow in the pre-BCRL 
population thus imposes a chronically high work rate on the lymphatic smooth muscle. We propose 
that this may be close to the maximum chronically sustainable work rate. Surgical removal of lymph 
nodes raises the outflow resistance to lymph in sheep (Kim et al. 2003). If the same is true in humans 
(perhaps exacerbated by the radiotherapy), then the previous level of lymph flow can only be 
maintained by a rise in P (afterload), further increasing the work rate (V/t) x P. Over a long 
period the increased work may cause a partial failure of lymphangion force generation (intrinsic 
smooth muscle failure) and/or vessel dilatation; the latter reduces the conversion of wall tension 
into pressure (LaPlace’s law) and may impair lymphatic valve competence. The ‘lymphatic work’ 
hypothesis has as its analogue in the chronic failure of a dilated heart resulting from a high preload 
and raised afterload (hypertension). The majority subset of women that avoid BCRL may do so partly 
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because their lymphatic system normally operates at a lower preload, leaving them with a greater 
reserve pump capacity. 
Additional pathogenic factors may also come into play after pump failure, for instance 
degenerative histopathological processes. A recent study described progressive histopathological 
changes in collector lymphatic vessels harvested from patients affected by lower limb lymphoedema 
after the surgical removal of lymph nodes for gynaecological cancers (Mihara et al. 2012). With 
increasing disease progression and severity the characteristics of the normal collector lymphatics 
were lost. In early stage lymphoedema most lymphatic vessels were normal or showed ectasia, 
which by LaPlace mechanics will tend to reduce pump pressure, even if contractile force were 
unimpaired. A minority of vessels had a thickened wall and narrower lumen. Sclerosis was 
commoner and ectasia less common with increasing severity of lymphoedema. Sclerosis of arm 
collector lymphatics would further impair lymphatic pumping and worsen the swelling. Severe 
sclerosis was observed in superficial lymphatics in the arm of a patient with refractory BCRL of 18 
years’ duration (Yamamoto et al. 2015). Inflammatory triggers for the above might be aggravated by 
the association between obesity and an abnormal inflammatory response, perhaps involving 
macrophage migration (Mehrara & Greene 2014; Ghanta et al. 2015). 
 
Impaired lymphatic transport dynamics in pre-BCRL patients following axillary surgery 
Transport into forearm from hand depot   The slight fall in pre-BCRL Ppump at 4.8 months post-
surgery was not statistically significant, yet at the same time point the lymphatic transport into the 
pre-BCRL forearm was roughly halved; dA/dtROI1 fell by 58 %, maximum ROI1 activity by 48 %. The 
contrast between the large fall in hand-to-forearm transport rate and relatively unchanged Ppump 
could be explained if the more distal contractile lymphatics (i.e. between hand depot and forearm) 
are weaker than proximal ones close to the cuff, which were still capable of generating a high Ppump. 
The data in Figure 4A versus C may thus be an early clue that distal lymphatics are the weakest link 
in the chain and begin to fail before more proximal lymphatics. 
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Transport into the axillary-supraclavicular region   The fall in dA/dtROI3 after surgery was much more 
pronounced in pre-BCRL (73 % reduction) than non-BCRL patients (28 % reduction), despite the 
relatively well maintained Ppump in the pre-BCRL group. The interpretation of dA/dtROI3 after surgery is 
complicated by the fact that some lymph nodes have been removed from this ROI. The reduced ROI3 
transport in both pre-BCRL and non-BCRL groups may be caused partly by increased lymph drainage 
resistance after axillary surgery; and the greater reduction in the pre-BCRL group may be caused by 
the slowed delivery of 99mTc-Nanocoll by the markedly impaired forearm transport vessels (transport 
in series). Other possibilities include more extensive axillary lymphatic trauma from the cancer 
surgery or radiotherapy (Whelan et al. 2015), which the study was not designed to explore. 
 
Limitations of present study 
To test further the hypothesis of a constitutively different Ppump in pre-BRL patients, measurements 
of Ppump and transport dynamics in both arms would have been valuable. This was not feasible in 
practice because of the demands it would have placed on the patients shortly before their cancer 
surgery. Ppump data at 2 years, after lymphoedema was established, would be useful, to check on the 
decline in function known to occur over several years (Modi et al. 2007). Many aspects of the 
proposed working hypothesis remain speculative and call for further work. For example, we are not 
aware of any comparative study of lymphatic smooth muscle structure and function in the distal 
collectors versus proximal collectors of the human arm; and apparently only one study (in sheep) has 
examined the effect of node removal on the hydraulic resistance to lymph transport out of a limb. 
 
Conclusions 
A disease model for BCRL emerges from the body of evidence presented here. BCRL-destined 
women have constitutively higher lymph loads and higher lymphatic pumping pressures. Breast 
cancer treatment per se has relatively little effect on maximum lymphatic pressure generation 
initially but nevertheless impairs lymph transport in those subsequently developing BCRL. Therefore 
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axillary lymphatic obstruction is not the sole explanation for BCRL. In BCRL-destined women the 
lymphatic contractile work rate is already high and if this is raised further by increased resistance to 
axillary drainage following cancer treatment and/or further increase in lymph load, the lymphatics 
are gradually tipped into chronic failure. This is analogous to high preload and high afterload cardiac 
failure in systemic hypertension. Reduced lymphatic pump activity then leads to overt clinical 
oedema. Pharmacological interventions aimed at reducing lymphatic pre- and/or afterload should, in 
theory, prevent BCRL if introduced at an earlier enough stage in patients identified as being at risk. 
Axillary lymphatic damage from surgery appears to compromise lymph drainage in those women 
constitutively predisposed but not in those women with constitutively lower lymphatic pressures 
and transport. This suggests, in theory, that women with higher lymphatic preloads could be 
identified as an ‘at risk’ group prior to cancer treatment. 
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Table 1. Surgical and pathological information. 
             
Patient Age Breast       Axillary No. of LNs  Tumour histology 
ID (yr) surgery      surgery removed (+) Grade Type      Size (mm) ER 
             
Pre-BCRL group 
004 69 WLE      SLNB  4 (0)  3 IDC        13  + 
015 42 WLE      ANC  22 (4)  3 IDC        45  – 
019 51 M      ANC  28 (10)  2 IDC, DCIS      43  + 
021† 74 M      ANC  14 (7)  2 IDC, DCIS      160  + 
022 72 M      ANC  17 (7)  3 IDC, DCIS*    43  + 
023† 50 M      ANC  4 (3)  3 IDC, DCIS      35  – 
028 51 WLE      ANC  32 (8)  2 IDC, DCIS      33  + 
030 49 M      ANC  10 (5)  2 IDC, DCIS*    70  + 
031 38 M      ANC  12 (0)  2 IDC, DCIS*    50  + 
039† 52 M      ANC  17 (1)  3 IDC        NR  NR 
Non-BCRL group 
003 37 M      ANC  15 (13)  2, 3 IDC        NR  + 
007† 64 M      ANC  33 (12)  3 IDC        75  + 
010 62 M      SLNB, ANC 9 (4)  2 IDC        35  + 
014 75 M      ANC  10 (4)  3 IDC        50  – 
017† 50 M      ANC  16 (5)  2 IDC        20  + 
018 43 WLE      SLNB  5 (0)  2 IDC, DCIS      35  + 
020 47 WLE      SLNB  1 (0)  1 IDC        NR  NR 
024 47 WLE      ANC  2 (0)  1 ICC        11  + 
025 67 WLE      SNLB  1 (0)  2 ILC        11, 15 + 
027 75 WLE      ANC  18 (5)  2 IDC, DCIS      43  + 
029 35 M      ANC  17 (3)  2 IDC        88  + 
032 52 WLE      ANC  31 (3)  3 IDC        22  + 
034 62 WLE      SLNB  3 (0)  2 IDC, ILC        14  + 
035 40 WLE      SLNB  1 (0)  1 IDC, DCIS      35  + 
036 47 M      ANC  19 (1)  3 IDC, DCIS      30  + 
037 42 WLE      ANC  20 (1)  3 IDC        56  – 
038 49 M      ANC  22 (6)  3 IDC        45  + 
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Pre-BCRL group - patients who later developed breast cancer related lymphoedema; non-BCRL group 
- patients who did not develop BCRL. ANC, axillary clearance surgery; DCIS, ductal carcinoma in situ; 
ER, oestrogen receptor status (positive/negative); ICC, invasive cribriform carcinoma; IDC, invasive 
ductal carcinoma; ILC, invasive lobular carcinoma; LN, lymph node, with the number positive for 
cancer in brackets; M, mastectomy; NR, not recorded; SLNB, sentinel lymph node biopsy; WLE, wide 
local excision; †died; *high-grade DCIS. All patients received radiotherapy. 
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Table 2. Ipsilateral and contralateral arm volumes in the pre-breast cancer related lymphoedema 
(pre-BCRL) patients and the non-BCRL patients, before and soon after axillary surgery (number of 
patients in brackets; means ± S.E.M.). 
             
  Pre-surgical arm volumes (ml)  Post-surgical arm volumes (ml) 
  Pre-BCRL (10) Non-BCRL (16) P1 Pre-BCRL (10) Non-BCRL (11) P1  
             
 
Ipsilateral 2312 ± 205 1894 ± 103 0.055 2369 ± 226 2007 ± 142 0.18 
Contralateral  2321 ± 192 1910 ± 107 0.054 2227 ± 202 2049 ± 150 0.48 
P2  0.88  0.59   0.040  0.34    
             
P1, comparison of the pre-BCRL and non-BCRL groups (unpaired t test); P2, comparison of the 
ipsilateral and contralateral arms (paired t test). In both groups, neither the ipsilateral nor the 
contralateral arm changed significantly in volume after surgery. 
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Table 3. Summary of measurements of lymphatic function in the pre-breast cancer related 
lymphoedema (pre-BCRL) patients and the non-BCRL patients, before and after axillary surgery 
(number of patients in brackets; means ± S.E.M.). 
             
  Pre-surgery         Post-surgery 
Pre-BCRL (10) Non-BCRL (16) P      Pre-BCRL (9) Non-BCRL (11) P 
             
Ppump (mmHg) 40.0 ± 2.6 23.1 ± 2.7 0.00071     36.7 ± 3.3 24.5 ± 3.4 0.022 
dA/dtROI1 (min-1) 2.32 ± 0.30 1.07 ± 0.35 0.052      0.98 ± 0.37 1.30 ± 0.10 0.45 
Peak countROI1 48.6 ± 8.11 33.7 ± 3.73 0.072      25.2 ± 8.62 40.2 ± 7.09 0.18 
dA/dtROI3 (min-1) 0.62 ± 0.02 0.40 ± 0.02 <0.0001     0.17 ± 0.01 0.29 ± 0.02 0.0003 
             
Ppump, lymphatic pump pressure. ROI, region of interest. dA/dtROI1, rate of rise of fractional count in 
ROI1 (x 103) determined by linear regression analysis of mean fractional counts over 2.5–10.0 min 
(both groups) and dA/dtROI3, rate of rise of fractional count in ROI3 (x 103) by linear regression 
analysis of mean fractional counts over 35–55 min (pre-BCRL) or 42.5–62.5 min (non-BCRL) (± S.E.). 
Peak countROI1, maximum fractional count in ROI1 (x 103). P, comparisons of the pre-BCRL group with 
the non-BCRL group, before or after surgery - 1Mann-Whitney test; comparison of regression slopes 
for dA/dt; unpaired t test for the other comparisons. See text and Figure 5 for pre-surgery versus 
post-surgery statistical comparisons. 
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Figure 1. A series of images from lymphatic congestion lymphoscintigraphy performed on the 
ipsilateral arm of a breast cancer patient who later developed BCRL. The scan was performed prior 
to axillary surgery. The regions of interest (ROI1: forearm, ROI2: subcuff, ROI3: axilla) are drawn in 
and the number of minutes elapsed since the injection are shown. The lymphatic tracer traversed 
the forearm in 2.5 min but is then held back by the congestion cuff at 60 mmHg (0–10 min), and at 
50 mmHg (10–20 min, not shown), until the cuff pressure is lowered to 40 mmHg (20–30 min). The 
pump pressure (Ppump, 40 mmHg here) is the cuff pressure at which the intra-lymphatic pressure 
overcame the surrounding occluding pressure, allowing tracer to pass into the axillary region ROI3. 
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Figure 2. Change in ipsilateral and contralateral arm volume following axillary surgery for the pre-
breast cancer-related lymphoedema (pre-BCRL) and the non-BCRL groups (pre-surgical volume = 100 
%, the post-surgical visit was at 21 weeks; means ± S.E.M., n). 
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Figure 3. Maximum pump pressure (Ppump) in collector lymphatics of the ipsilateral arm in breast 
cancer patients prior to axillary surgery. The 10 pre-breast cancer-related lymphoedema (pre-BCRL) 
and 16 non-BCRL patients are shown separately (left and centre arrays). Ppump for the pooled group 
of the 26 patients (right array) shows a bimodal distribution. The horizontal lines indicate the means 
(40.0, 23.1 and 29.6 mmHg, respectively). Ppump was highly significantly greater in the pre-BCRL 
patients than the non-BCRL patients (P = 0.0007, n = 10 and 16, Mann-Whitney test). 
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Figure 4. Radioactive counts (expressed as a fraction of injected activity) recorded in each region of 
interest (ROI) in the ipsilateral arm during lymphatic congestion lymphoscintigraphy (means ± 
S.E.M.) plotted against time since hand depot injection. A. Pre-breast cancer-related lymphoedema 
(pre-BCRL) patients before surgery. B. Non-BCRL patients before surgery. C. Pre-BCRL patients 21 
weeks after surgery. D. Non-BCRL patients 21 weeks after surgery. ROI1 - forearm; ROI2 - subcuff; 
ROI3 - axilla. The cuff pressure (Pcuff) in mmHg is shown above each time interval. Before surgery 
(frame A versus B), the pre-BCRL fractional counts in ROI1 rose faster than non-BCRL counts over 
2.5–10 min (greater dA/dtROI1, see text) and reached a higher peak. Also, after Pcuff was lowered 
below Ppump the pre-BCRL counts in ROI3 rose faster than non-BCRL counts (greater dA/dtROI3). At 21 
weeks after surgery, transport dynamics in the pre-BCRL patients were substantially reduced 
35 
 
compared with prior to surgery (frame A versus C), whereas transport dynamics in the non-BCRL 
patients were not reduced after surgery (frame B versus D). 
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Figure 5. Effect of surgery on 99Tc-Nanocoll accumulation in the ipsilateral arm at 21 weeks in pre- 
breast cancer-related lymphoedema (pre-BCRL) and non-BCRL patients. A. Maximum count in region 
of interest (ROI)1 (forearm; n = 9 pairs for pre-BCRL, 11 pairs for non-BCRL). B. Rate of rise of activity 
(dA/dt) in ROI1. C. Rate of rise of activity in ROI3 (axillary-supraclavicular region). Mean ± S.E.M., all 
values x 103. dA/dt was quantified by linear regression analysis of plots of mean fractional counts 
versus time. dA/dtROI1 describes transport rate from depot into forearm during the initial trapped 
lymph phase (2.5–10.0 min). dA/dtROI3 describes transport rate beyond the cuff over 20 min after 
cuff pressure was reduced below lymphatic pump pressure. P, comparisons of pre-surgery with post-
surgery - paired t test (A); comparison of regression slopes (B, C). Surgery greatly reduced arm 
lymphatic transport in pre-BCRLs, with less effect on non-BCRLs. 
